{"id":6496,"date":"2015-12-14T13:07:00","date_gmt":"2015-12-14T13:07:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&#038;p=6496"},"modified":"2021-12-14T13:10:05","modified_gmt":"2021-12-14T13:10:05","slug":"current-treatment-options-for-inflammatory-bowel-diseases-and-future-perspectives","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/de\/professional\/scientific-corner\/current-treatment-options-for-inflammatory-bowel-diseases-and-future-perspectives\/","title":{"rendered":"Current Treatment Options for Inflammatory Bowel Diseases and Future Perspectives"},"content":{"rendered":"<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p>TARO OSADA\uff0a, SUMIO WATANABE\uff0a, Juntendo Medical Journal61 (6), 588-596<br><\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p>In recent years, landmark progress has been made in the treatment of patients with inflammatory bowel<br>diseases (IBD). The anti-tumour necrosis factor (TNF)-\u03b1 antibody era has shown that mucosal healing is a key<br>therapeutic goal, and may predict the sustainability of remission or resection-free survival in IBD patients.<br>Further, the anti-TNF-\u03b1 antibody infliximab (IFX) became an alternative medication for refractory UC in 2010<br>under the Japan national health reimbursement scheme. However, to induce remission in steroid-refractory UC,<br>currently several therapeutic options are available in Japan including cytapheresis, tacrolimus, and anti-TNF-\u03b1<br>biologics, but as yet, there are no guidelines for the sequence and timing of these therapeutic interventions.<br>Additionally, there are many patients who do not respond, or are intolerant, to anti-TNF-\u03b1 biologics. Recently,<br>new strategies like faecal microbiota transplantation and anti-leucocyte infiltration have been tested for induction<br>and maintenance of remission in IBD patients. This paper provides an overview of the latest treatment options and<br>future perspectives in IBD therapy<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><a href=\"https:\/\/www.jstage.jst.go.jp\/article\/jmj\/61\/6\/61_588\/_pdf\/-char\/en\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.jstage.jst.go.jp\/article\/jmj\/61\/6\/61_588\/_pdf\/-char\/en<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>TARO OSADA\uff0a, SUMIO WATANABE\uff0a, Juntendo Medical Journal61 (6), 588-596 In recent years, landmark progress has been made in the treatment of patients with inflammatory boweldiseases (IBD). The anti-tumour necrosis factor (TNF)-\u03b1 antibody era has shown that mucosal healing is a keytherapeutic goal, and may predict the sustainability of remission or resection-free survival in IBD patients.Further, [&hellip;]<\/p>\n","protected":false},"template":"","scientific_tags":[70,134,159,380,306],"class_list":["post-6496","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-anti-tnf","scientific_tags-biologics","scientific_tags-crohns-disease","scientific_tags-cytapheresis","scientific_tags-ulcerative-colitis"],"acf":{"sc_authors":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Current Treatment Options for Inflammatory Bowel Diseases and Future Perspectives - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/current-treatment-options-for-inflammatory-bowel-diseases-and-future-perspectives\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Current Treatment Options for Inflammatory Bowel Diseases and Future Perspectives - Adacyte\" \/>\n<meta property=\"og:description\" content=\"TARO OSADA\uff0a, SUMIO WATANABE\uff0a, Juntendo Medical Journal61 (6), 588-596 In recent years, landmark progress has been made in the treatment of patients with inflammatory boweldiseases (IBD). The anti-tumour necrosis factor (TNF)-\u03b1 antibody era has shown that mucosal healing is a keytherapeutic goal, and may predict the sustainability of remission or resection-free survival in IBD patients.Further, [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/current-treatment-options-for-inflammatory-bowel-diseases-and-future-perspectives\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2021-12-14T13:10:05+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data1\" content=\"1\u00a0Minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/current-treatment-options-for-inflammatory-bowel-diseases-and-future-perspectives\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/current-treatment-options-for-inflammatory-bowel-diseases-and-future-perspectives\/\",\"name\":\"Current Treatment Options for Inflammatory Bowel Diseases and Future Perspectives - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2015-12-14T13:07:00+00:00\",\"dateModified\":\"2021-12-14T13:10:05+00:00\",\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/current-treatment-options-for-inflammatory-bowel-diseases-and-future-perspectives\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Current Treatment Options for Inflammatory Bowel Diseases and Future Perspectives - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/current-treatment-options-for-inflammatory-bowel-diseases-and-future-perspectives\/","og_locale":"de_DE","og_type":"article","og_title":"Current Treatment Options for Inflammatory Bowel Diseases and Future Perspectives - Adacyte","og_description":"TARO OSADA\uff0a, SUMIO WATANABE\uff0a, Juntendo Medical Journal61 (6), 588-596 In recent years, landmark progress has been made in the treatment of patients with inflammatory boweldiseases (IBD). The anti-tumour necrosis factor (TNF)-\u03b1 antibody era has shown that mucosal healing is a keytherapeutic goal, and may predict the sustainability of remission or resection-free survival in IBD patients.Further, [&hellip;]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/current-treatment-options-for-inflammatory-bowel-diseases-and-future-perspectives\/","og_site_name":"Adacyte","article_modified_time":"2021-12-14T13:10:05+00:00","twitter_card":"summary_large_image","twitter_misc":{"Gesch\u00e4tzte Lesezeit":"1\u00a0Minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/current-treatment-options-for-inflammatory-bowel-diseases-and-future-perspectives\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/current-treatment-options-for-inflammatory-bowel-diseases-and-future-perspectives\/","name":"Current Treatment Options for Inflammatory Bowel Diseases and Future Perspectives - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2015-12-14T13:07:00+00:00","dateModified":"2021-12-14T13:10:05+00:00","inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/current-treatment-options-for-inflammatory-bowel-diseases-and-future-perspectives\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/scientific-corner\/6496","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/media?parent=6496"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/scientific_tags?post=6496"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}